Clinuvel Pharmaceuticals (ASX:CUV) reported Thursday that its earnings per diluted share in the fiscal first half rose to AU$0.28 from AU$0.212 a year earlier.
Analysts polled by Visible Alpha were expecting an EPS of AU$0.20.
Revenue for the six months ended Dec. 31, 2024, was AU$35.6 million, up from AU$32.3 million in the same period a year earlier. Analysts surveyed by Visible Alpha expected AU$35.6 million.
The company's shares rose past 8% in recent Thursday trade.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。